Board of Directors

Shaun R. Bagai

Director of Board and Chief Executive Officer

Shaun R. Bagai

Chief Executive Officer

Mr. Bagai brings over 21 years of medical technology expertise with a proven track record in leadership roles in clinical research, physician training, sales, marketing, and market development. He has successfully launched novel technologies into regional and global marketplaces in large corporations as well as growth-phase companies. He was instrumental in developing the European market for renal denervation for the treatment of hypertension which led to the acquisition of the first renal denervation company, Ardian, Inc., by Medtronic in 2011 for over $850M. Prior to joining RenovoRx, Mr. Bagai led global market development for HeartFlow, Inc., which included directing Japanese market research, regulatory/payer collaboration, and Key Opinion Leader development to create value resulting in the creation of HeartFlow-Japan. Prior to leaving HeartFlow, he also successfully orchestrated their largest clinical trial and contracted HeartFlow’s first global customers. Mr. Bagai is a graduate from the University of California, Santa Barbara with a B. Sc. in Biology/Pre-med.

Ramtin Agah, MD

Ramtin Agah, MD

Chairman of Board, Chief Medical Officer and Founder

Ramtin Agah, MDRamtin Agah, MD

Chairman of Board, Chief Medical Officer and Founder

Dr. Agah is currently Interventional Cardiologist at El Camino Hospital, Mountain View. He was previously Assistant Professor of Internal Medicine with the Division of Cardiology, University of Utah. Dr. Agah completed a Fellowship in Interventional Cardiology with Cleveland Clinic Foundation, a Residency in Internal Medicine with Baylor College of Medicine, Houston, Texas, and a Fellowship in Cardiology with U.C.S.F. in San Francisco, CA. He is a MD graduate of University of Texas Southwestern Medical School. Dr. Agah is a founder and the originator of the RenovoRx technology.

Laurence J. MartonLaurence J. Marton


Dr. Marton serves as a consultant to industry and to nonprofit, government, and academic institutions. In the nonprofit sector, Dr. Marton serves on the Board of Trustees of the American Association for Cancer Research Foundation, and on the Board of Directors of Cancer Commons, Rapid Science, and the Bay Area American Committee for the Weizmann Institute of Science. In the for-profit sector, he serves on the Board of Directors of Cellsonics, Dategra, Matternet, Microsonic Systems, Pathologica, RenovoRx, TOMA Biosciences, and xCures; is Chair of the Scientific Advisory Board of PharmaJet; is an advisor to Ciitizen and the Precision Medicine World Conference; and is on the Editorial Board of the Journal of Precision Medicine.

Previously, Dr. Marton was Dean of the University of Wisconsin Medical School and Chaired the Department of Laboratory Medicine at UCSF, where he was a Professor in the Departments of Laboratory Medicine and Neurological Surgery. Dr. Marton received his MD from the Albert Einstein College of Medicine and his BA from Yeshiva University.

Una S. Ryan, PhD, OBEUna S. Ryan, PhD, OBE


Una S. Ryan, PhD, OBE is Managing Director Golden Seeds (Silicon Valley), an angel investing group focused on women-led companies. She is currently Research Professor of Medicine at BU School of Medicine and serves on its Board of Visitors. Her board positions include AMRI (Lead Director, Nominating and Compensation committees) and MSH (Audit and Compensation committees).
Dr. Ryan was most recently President and CEO of Diagnostics For All (DFA), a non-profit organization developing inexpensive diagnostics for global health and agricultural uses. Previously, she was President and CEO of AVANT Immunotherapeutics, Inc, (NASDAQ) a company developing vaccines and immunotherapeutics for cancer, travelers, food safety, and global health, and also a member of its Board of Directors. Prior to AVANT, she was director of Health Sciences at Monsanto Company. Before that, she held a number of positions in academia, including Research Professor of Surgery at Washington University School of Medicine in St. Louis and Professor of Medicine at the University of Miami School of Medicine. She was also Chair of the Massachusetts Biotechnology Council, served on its Board, as well as the Biotechnology Industry Organization, New England Healthcare Institute, Board of Associates of the Whitehead Institute, Strategy & Policy Council of the MIT Center for Biomedical Innovation, Massachusetts Life Sciences Collaborative Leadership Council and the Goddard Council on science, technology, engineering and mathematics education.

Dr. Ryan holds a PhD in Cellular and Molecular Biology from Cambridge University and BS degrees in Zoology, Microbiology and Chemistry from Bristol University. She received an Honorary Doctor of Science degree from Bristol University in 2009. In 2007, Dr. Ryan received the Albert Einstein Award for outstanding achievement in the life sciences. In 2002 Her Majesty Queen Elizabeth II awarded Dr. Ryan the Order of the British Empire (OBE) for services to research, development and promotion of biotechnology.

Maky Zanganeh, DDS, MBAMaky Zanganeh, DDS, MBA


Founder and CEO of Maky Zanganeh and Associates, Inc., an investment, consulting and management group.

Maky Zanganeh has more than 16 years of strategic planning, management, corporate, clinical, business and marketing experience in the pharmaceutical, medical device and technology industries.

Prior to founding Maky Zanganeh & Associates, Maky was the COO at Pharmacyclics, Inc. where she oversaw all clinical, research, commercial and business-related matters. Under her leadership, the company was able to achieve four FDA labels, with three Breakthrough Therapy Designations, in 14 months; a feat which has never been accomplished by any company before.  Maky also drove the multi-million dollar collaboration and license deal for ibrutinib with Janssen Biotech Inc. in 2011 and the subsequent sale of the company for $21 billion dollars in 2015 to AbbVie, Inc.; the second largest biopharmaceutical sale ever in the industry.

  • The deal with Janssen Biotech received the award of the “Best Biotech Transaction” in 2011.
  • Under her leadership in 2015, Pharmacyclics was awarded the prestigious Prix Galien for Best Pharmaceutical Agent.  This award is the biomedical industry’s highest accolade, the Prix Galien Award recognizes outstanding achievement in the development of new therapies.

Previously, Maky held senior and executive positions including International Product Manager for IRCAD-EITS, General Director Pos De Competitive for Therapeutic Innovation and President Director General (CEO) of Europe, Middle East and Africa and World-wide Vice President of Training and Education for Computer Motion (which was acquired in 2003 by Intuitive Surgical).

Maky is currently on the Board of Directors of Human Longevity Inc., Renovorx, Radial Medical and Pulse Biosciences.

Maky earned her Doctor of Dental Surgery and her Master of Business Administration in International Business in France. She is a licensed investment advisor (Series 65) and has her dentistry license. She is fluent in French, German, Farsi and English. Dr Zanganeh earned the Fierce Biotech “2013 Top Women in Biotech” award and the Ernst & Young Entrepreneur of the Year award in 2013.

Angela MacfarlaneAngela Macfarlane


Ms. Macfarlane currently serves as CEO of Voyant Biotherapeutics, LLC, an early-stage biotech company dedicated to solving age-related macular degeneration. She founded and also serves as a Managing Partner of ForSight Labs, LLC an ophthalmic incubator formed in 2005 in partnership with Dr. Eugene de Juan, Jr. MD, and The Foundry. ForSight has started seven VISION companies in both therapeutics and medical devices — including Transcend Medical, Inc. (acquired by ALCON), ForSight Newco II, Inc. (acquired by QLT), NexisVision, Inc. (licensed), Forsight VISION4, Inc. (acquired by Roche), ForSight VISION5, Inc. (acquired by ALLERGAN), ForSight VISION6, Inc. (private/strategic partnership), and FSV7, LLC (private), focused on developing therapeutics for CNS disorders. Ms. Macfarlane served as the operating CEO of 3 ForSight companies, including as founding CEO through acquisition for ForSight VISION4, Inc. (Acquired by ROCHE), and ForSight VISION5, Inc., (Acquired by Allergan).

Previously, Ms. Macfarlane served as Chief Technology Counsel to The Foundry, a medical technology incubator, and Technology Counsel for Thomas J. Fogarty, M.D., a renowned physician/entrepreneur where she participated in the formation and/or development of 9 companies. She previously served on the senior management teams and counsel at TransVascular, Inc. (acquired by Medtronic), AneuRx, Inc. (acquired by Medtronic), and VidaMed Inc. (through IPO).

Ms. Macfarlane is an inventor on 25 U.S. issued patents and received her BA in Business Administration from San Francisco State University, and her J.D. from Golden Gate University School of Law. She currently serves on the board of the Fogarty Institute for Innovation and is a mentor in the Ferolyn Powell Leadership Program.

David DiamondDavid Diamond


Mr. Diamond provides strategic guidance and operational oversight to CEOs and Board Directors in the Life Sciences industry. Mr. Diamond has significant experience assisting management teams and board directors with capital financing and strategic business planning nationally and internationally. He has built strong relationships with Wall Street Bankers. Mr. Diamond is the National Life Sciences and Technology Practice Lead at Mayer Hoffman McCann P.C. a national CPA firm. He has over 30 years of experience in both public accounting and industry. He is an active CPA and a former auditor. He is the Audit Chair and Board member for Oncotelic, Inc. Additionally, he was a Board member for Kreston International ($2 billion CPA network) for seven years and a San Diego Venture Group board member for seven years and was a Founding Member of UCSD Connect. Mr. Diamond is a Certified Director in Corporate Governance from UCLA Anderson Graduate School of Management and a CPA in USA, Israel and South Africa.